Preparation method for and use of antibacterial hemostatic hydrogel loaded with composite nanoparticles

By loading drugs on mesoporous polydopamine nanospheres and combining them with specific compounds to form composite nanoparticles and hydrogels, the problem of low mechanical properties and drug release rate in traumatic brain injury is solved, and the problem of low mechanical properties and drug release rate of hydrogels is achieved. Efficient antibacterial hemostasis and repair effects.

WO2024244536A1PCT designated stage expired Publication Date: 2024-12-05BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/075968
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2024-02-05
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The existing hydrogels lack mechanical properties and stability in the repair of traumatic brain injury, making it difficult to achieve the effect of stopping hemostatic and repairing nerve factors, and the drug release rate is low and the stability is not high.

Method used

Antibacterials are prepared by loading hydrophobic drugs on mesoporous polydopamine nanospheres, combining tertiary amine compounds, natural polymers and crosslinking agents, and forming composite nanoparticles, reacting with blank hydrogel interaction forces and Schiff base. Hemostatic hydrogel achieves controlled release of drugs and high-efficiency drug loading.

Benefits of technology

The prepared antibacterial hemostasis hydrogel has good mechanical properties, adhesion properties, self-healing properties and biocompatibility, and can effectively stabilize the drug components, achieve high drug loading and encapsulation rates, and achieve good drug release. and exhibits efficient anti-inflammatory and hemostatic properties in traumatic brain injury repair.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024075968_05122024_PF_FP_ABST
    Figure CN2024075968_05122024_PF_FP_ABST
Patent Text Reader

Abstract

A preparation method for and a use of an antibacterial hemostatic hydrogel loaded with composite nanoparticles. The preparation method comprises the following steps: (1) synthesis of composite nanoparticles, wherein the composite nanoparticles are prepared by loading a hydrophobic drug on mesoporous polydopamine nanospheres; (2) synthesis of a blank hydrogel, wherein the blank hydrogel is formed by mixing a solution A and a solution B; and (3) synthesis of a drug-loaded hydrogel, wherein the drug-loaded hydrogel is formed by mixing the blank hydrogel and the composite nanoparticles. The composite nanoparticles and the blank hydrogel form an antibacterial hemostatic gel by means of physical interaction, Schiff base reaction, etc. The antibacterial hemostatic gel has the function of absorbing tissue exudate and antibacterial performance, and is applicable to the filling and anti-inflammatory of a postoperative site of brain injury and nerve repair treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Preparation method and application of antibacterial hemostatic hydrogel loaded with composite nanoparticles Technical Field

[0001] The present invention belongs to the field of biomedical materials and has a classification number of C08J3 / 075. Specifically, it relates to an antibacterial hemostatic hydrogel loaded with composite nanoparticles and a preparation method thereof. Background Art

[0002] Traumatic brain injury (TBI) is a common neurosurgery disease and a major global health and socioeconomic problem. The secondary injury mechanism during TBI is an important cause of death, and the secondary injury mainly affects the neuron body, dendrites, synapses and other types of nerve cells.

[0003] Hydrogel is a type of extremely hydrophilic three-dimensional network structure gel that swells rapidly in water and can retain a large volume of water in this swollen state without dissolving. Currently, hydrogel is often used as a wound repair material, but the mechanical properties and stability of hydrogel are generally poor, which can easily lead to wound exposure and increase the risk of infection. Moreover, it only has antibacterial properties and cannot achieve the effects of anti-inflammatory and repairing neural factors. Therefore, the development of hydrogel in the field of traumatic brain injury repair needs to be promoted.

[0004] Chinese patent CN114984244A discloses a hyperbranched polylysine-containing hydrogel carrier material and a preparation method thereof. The hyperbranched polylysine and aldehyde hyaluronic acid are simply physically mixed to form a hydrogel, and then the drug and the hydrogel are simply mixed by ultrasound. Although the hydrogel has an anti-inflammatory effect to a certain extent, it cannot achieve the effect of stopping bleeding and repairing nerve factors. In addition, simply mixing the drug and the hydrogel results in a low drug release rate and low stability.

[0005] Chinese patent CN114668897B discloses an antibacterial, adherent, injectable, and healable hydrogel, as well as its preparation method and application. The hydrogel, synthesized from ingredients such as quaternized chitosan, mesoporous polydopamine nanoparticles, and gelatin, has certain mechanical properties, adhesion, self-healing properties, and antibacterial properties, but it cannot achieve hemostatic and anti-inflammatory effects.

[0006] Summary of the Invention

[0007] In order to solve the above problems, the first aspect of the present invention provides a method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles, which is characterized by comprising the following steps: (1) synthesis of composite nanoparticles; the composite nanoparticles are composed of mesoporous polydopamine nanospheres loaded with hydrophobic drugs; (2) synthesis of blank hydrogel; the blank hydrogel is formed by mixing liquid A and liquid B; (3) synthesis of drug-loaded hydrogel; the drug-loaded hydrogel is formed by mixing blank hydrogel and composite nanoparticles.

[0008] Further preferably, the hydrophobic drug is an anti-inflammatory drug for treating brain injury.

[0009] Preferably, the raw materials for preparing liquid A in step (2) include tertiary amine compounds, natural polymers and epihalohydrin.

[0010] Further preferably, the tertiary amine compound includes at least one of dimethyldodecyl tertiary amine, dimethyloctyl tertiary amine, and dimethyltetradecyl tertiary amine, the natural polymer is a chitosan derivative, and the epihalohydrin is epichlorohydrin.

[0011] More preferably, the tertiary amine compound is dimethyldodecyl tertiary amine, and the natural polymer is carboxymethyl chitosan.

[0012] Preferably, the preparation method of the liquid A is: first synthesize the antibacterial agent, and then mix the antibacterial agent with the natural polymer solution and react for 3-6 hours to obtain the liquid A.

[0013] More preferably, the preparation method of the liquid A is: first synthesize the antibacterial agent, and then mix the antibacterial agent with the natural polymer solution and react for 3-5 hours to obtain the liquid A.

[0014] More preferably, the preparation method of the liquid A is: first synthesize the antibacterial agent, and then mix the antibacterial agent with the natural polymer solution and react for 4 hours to obtain the product.

[0015] Preferably, in the method for preparing liquid A, the amount of the antibacterial agent used is 10-20 mg.

[0016] Further preferably, in the method for preparing liquid A, the amount of the antibacterial agent used is 13-17 mg.

[0017] Further preferably, in the method for preparing liquid A, the amount of the antibacterial agent used is 15 mg.

[0018] Preferably, the raw materials for preparing liquid B in step (2) include a cross-linking agent and a hemostatic polypeptide.

[0019] More preferably, the cross-linking agent is oxidized dextran.

[0020] Preferably, the preparation method of liquid B in step (2) is: mixing the cross-linking agent and the hemostatic polypeptide at 20-30° C. and reacting for 1-4 hours to obtain the liquid.

[0021] More preferably, the preparation method of liquid B in step (2) is: mixing the cross-linking agent and the hemostatic polypeptide at 25° C. and reacting for 1-3 hours to obtain the liquid.

[0022] More preferably, the preparation method of liquid B in step (2) is: mixing the cross-linking agent and the hemostatic polypeptide at 25° C. and reacting for 2 hours to obtain the liquid.

[0023] Preferably, the usage amount of the hemostatic polypeptide is 5-15 mg.

[0024] More preferably, the amount of the hemostatic polypeptide used is 8-12 mg.

[0025] More preferably, the usage amount of the hemostatic polypeptide is 10 mg.

[0026] Preferably, the volume ratio of liquid A to liquid B in step (2) is 1:(2-4).

[0027] Further preferably, in step (2), the volume ratio of liquid A to liquid B is 1:(2.5-3.5).

[0028] Further preferably, in step (2), the volume ratio of liquid A to liquid B is 1:3.

[0029] Preferably, the mass percentage of liquid A is 1-3 wt %, and the mass percentage of liquid B is 3-6 wt %.

[0030] Further preferably, the mass percentage of liquid A is 1.5-2.5 wt%, and the mass percentage of liquid B is 4-6 wt%.

[0031] Further preferably, the mass percentage of liquid A is 2 wt %, and the mass percentage of liquid B is 5 wt %.

[0032] The second aspect of the present invention provides a use of the antibacterial hemostatic hydrogel loaded with composite nanoparticles in the preparation of wound repair materials.

[0033] The present application limits the addition amount of the antibacterial agent to 10-20 mg. At this time, the grafting rate of the antibacterial agent EPDMDAC in carboxymethyl chitosan is moderate, which will not lead to the subsequent addition of nanomaterials. On the one hand, its grafting rate is too high, resulting in the occupation of the active sites that can be connected to the composite material, which not only affects the hemostatic performance of the hydrogel, but also on the other hand, when a blank hydrogel is subsequently synthesized, the number of reaction sites drops sharply, resulting in a decrease in the rheological and adhesion properties of the blank hydrogel. Similarly, on this basis, the addition amount of the hemostatic polypeptide is further limited to 8-12 mg.

[0034] The present application limits the ratio between the EPD-CMC solution and the RAD-OD solution in the blank hydrogel to 1:(2-4). A reduction in the ratio will lead to a decrease in the cross-linking density of the hydrogel, change the gel-sol transition point, and cause the loss modulus of the hydrogel to be much smaller than the storage modulus, resulting in viscous deformation and a liquid state of the material, which will weaken the adhesion performance of the gel. When the ratio of the two increases, the cross-linking density of the two increases, the loss modulus of the hydrogel is much larger than the storage modulus, the hydrogel becomes solid, and its adhesion and self-healing properties are relatively weakened. Beneficial effects:

[0035] (1) The present invention utilizes the hydrophobic pores on the surface of mesoporous polydopamine nanospheres to load the anti-inflammatory hormone drug dexamethasone to obtain composite nanoparticles, which have the properties of anti-oxidation, anti-inflammatory, and inner layer repair.

[0036] (2) The present invention forms an antibacterial hemostatic gel by combining composite nanoparticles and blank hydrogel through interaction forces and "Schiff base reaction". The antibacterial hemostatic gel has the ability to adsorb tissue exudate, has antibacterial properties, and can achieve controlled release of dexamethasone. It has antioxidant properties and can synergistically control the inflammatory microenvironment of the lesion site. It has high biocompatibility and tissue affinity and is suitable for filling and anti-inflammatory repair treatment of the postoperative site of brain injury.

[0037] (3) The antibacterial hemostatic gel prepared by the present invention has good stability, good mechanical properties, and good adhesion, self-healing and injectability. It also has good biocompatibility and self-degradation properties, can effectively stabilize drug components, and has high drug loading rate and encapsulation rate, which can achieve a good drug release effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 shows the particle size distribution of mesoporous polydopamine nanospheres (mPDA) and composite nanomaterials (mPDA@DXMS).

[0039] Figure 2 shows the potential distribution of mPDA and mPDA@DXMS.

[0040] Figure 3 (left) is the TEM image of mPDA, and (right) is the TEM image of mPDA@DXMS.

[0041] Figure 4 shows the release curve obtained from the in vitro drug release experiment of mPDA@DXMS.

[0042] FIG5 is a graph showing the UV-visible absorption spectra of dexamethasone (black line), mesoporous polydopamine nanospheres (red line), and mPDA@DXMS (blue line) in Example 1.

[0043] FIG6 is an infrared spectrum of liquid A synthesized using different amounts of antimicrobial agents when synthesizing liquid A.

[0044] Figure 7 shows the infrared spectra of liquid A (CMC-EPD), antibacterial agent (EPD) and carboxymethyl chitosan (CMC).

[0045] FIG8 is an infrared spectrum of liquid B (OD-RAD), hemostatic polypeptide (RAD) and oxidized dextran (OD).

[0046] Figure 9 shows the appearance of the blank hydrogel (left) and the antibacterial hemostatic hydrogel loaded with composite nanoparticles (right) in Example 1. It can be seen from the figure that the DXMS@mPDA@Gel composite hydrogel is a uniform and transparent colloid without obvious particle deposition. It is preliminarily judged that the DXMS@mPDA composite nanoparticles are successfully and evenly adsorbed in the gel pores.

[0047] The left image of Figure 10 is an SEM image of a blank hydrogel, and the right image is an antibacterial hemostatic hydrogel loaded with composite nanoparticles. In Figure 11, (1) is a rheological property graph of the blank hydrogel and DXMS@mPDA@Gel, (2) is a shear rate-viscosity relationship curve in the rheological properties of the blank hydrogel and DXMS@mPDA@Gel, (3) is a step strain test in the rheological properties of the blank hydrogel and DXMS@mPDA@Gel, and (4) is a graph measuring the self-healing performance of the hydrogel in Example 1.

[0048] FIG12 is a graph showing the degradation rates of blank hydrogel and antibacterial hemostatic hydrogel loaded with composite nanoparticles.

[0049] FIG13 is a graph showing the adhesion performance of the antibacterial hemostatic hydrogel loaded with composite nanoparticles in Example 1 on various organs of mice.

[0050] FIG14 is an antibacterial experiment of the blank hydrogels in Comparative Example 4 and Example 1 of the present invention, wherein FIG14 (a) is a control experiment, FIG14 (b) is added with the blank hydrogel in Comparative Example 4, and FIG14 (c) is added with the blank hydrogel in Example 1.

[0051] FIG15 is a hemostasis experiment of the blank hydrogels in Comparative Example 4 and Example 1 of the present invention, wherein FIG15 is a control experiment, FIG15 is a hemostasis experiment of the blank hydrogel in Comparative Example 4, and FIG15 is a hemostasis experiment of the blank hydrogel in Example 1. DETAILED DESCRIPTION

[0052] 1. The experimental materials used in the following examples are shown in the following table:

[0053] 2. The test instruments used in the experiment are shown in the following table:

[0054] Example 1

[0055] A method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles comprises the following steps: (1) synthesizing composite nanoparticles; the composite nanoparticles are formed by loading a hydrophobic drug onto mesoporous polydopamine nanospheres; (2) synthesizing a blank hydrogel; the blank hydrogel is formed by mixing liquid A and liquid B; and (3) synthesizing a drug-loaded hydrogel; the drug-loaded hydrogel is formed by mixing the blank hydrogel and the composite nanoparticles.

[0056] The hydrophobic drug is dexamethasone (DXMS).

[0057] The synthesis method of the composite nanoparticles in step (1) is as follows:

[0058] First, 1.0 g of nonionic surfactant poloxamer and 0.5 g of dopamine were dissolved in 100 mL of 50% ethanol solution, covered with plastic wrap, and holes were evenly pierced on the plastic wrap with a 200 uL pipette tip. The mixture was stirred at room temperature on a stirring table until dissolved to obtain a clear and transparent solution. Then, 2 mL of 3,3',5,5'-tetramethylbenzidine (TMB) was added dropwise at a speed of 500 rpm / min, and stirred for 30 min to obtain a white milky solution. At the same speed, the temperature was adjusted to 25 ° C, 5 mL of ammonia water was added dropwise, and a black solution was obtained after stirring for 2 h. The reaction was continued for 4 h to obtain a reaction solution. 2 mL of the reaction solution was aspirated into a 2 mL centrifuge tube (24 2 mL centrifuge tubes were prepared in advance), and the mixture was centrifuged in a refrigerated centrifuge (the centrifugal speed was 13500 rpm / min and the time was 15 min). The supernatant was discarded and 2 mL Wash with 50% ethanol and shake well, continue centrifugation, repeat the above operation twice, and finally add 500 μL pure water to dissolve the precipitate after centrifugation, and resuspend by ultrasonication to obtain mesoporous polydopamine nanosphere solution (mPDA);

[0059] A 1 mL, 1 mg / mL dexamethasone (DXMS) solution was added to a 1 mL, 1 mg / mL mesoporous polydopamine nanosphere solution. After stirring at 400 rpm / min for 24 h, the mixture was centrifuged and washed to obtain a composite nanomaterial (mPDA@DXMS).

[0060] The raw materials for preparing liquid A in step (2) include tertiary amine compounds, natural polymers and epihalohydrin, wherein the tertiary amine compound is dimethyldodecyl tertiary amine (EPD), the natural polymer is carboxymethyl chitosan, and the epihalohydrin is epichlorohydrin.

[0061] The preparation method of the solution A is as follows: first synthesize the antibacterial agent, then mix 15 mg of the antibacterial agent with 5 mL of 3% carboxymethyl chitosan solution (CMC) for 4 hours, and then dialyze with a 1000 KDa dialysis bag for 24 hours to obtain the solution.

[0062] The antibacterial agent (EPDMDAC) is synthesized as follows: 0.01 mmol of dimethyldodecyl tertiary amine and 0.04 mmol of epichlorohydrin are reacted at 80°C for 1 hour. When the mixed reactant solution turns from transparent to dark yellow, the reaction product is precipitated with diethyl ether and centrifuged to obtain crude EPDMDAC. The crude EPDMDAC is then ultrasonically washed with diethyl ether three times and dried in a vacuum to obtain the antibacterial agent (EPDMDAC).

[0063] The raw materials for preparing liquid B in step (2) include a cross-linking agent and a hemostatic polypeptide.

[0064] The cross-linking agent is oxidized dextran (OD), and the preparation method of the oxidized dextran is as follows: dissolving 5 g of dextran in 250 mL of distilled water to obtain a dextran solution, then dissolving 5 g of sodium periodate in 5 mL of distilled water to obtain a sodium periodate solution, adding the sodium periodate solution dropwise to the dextran solution, and then stirring at room temperature in the dark for 3.5 hours to obtain a mixture, finally, adding 3 mL of ethylene glycol to the mixture to react unreacted sodium periodate, and finally stirring for another 1 hour, dialyzing the resulting product against distilled water (MWCO 3500Da) for 3 days and freeze-drying to obtain the oxidized dextran.

[0065] The preparation method of liquid B in step (2) is as follows: 10 mg of hemostatic polypeptide is added to 5 ml of 5 wt% oxidized dextran solution at 25° C. and reacted for 2 hours; the nucleotide sequence of the hemostatic polypeptide is arginine (R)-alanine (A)-aspartic acid (D)-alanine (A)-arginine (R)-glycine (G)-aspartic acid (D)-lysine (K).

[0066] (2) Synthesis of blank hydrogel: 2 wt% of liquid A and 5 wt% of liquid B (using distilled water as solvent) were mixed in a volume ratio of 1:3 to obtain a blank hydrogel.

[0067] (3) Synthesis of drug-loaded hydrogel: The composite nanoparticle solution was dispersed in liquid A at a volume ratio of 1:1 to obtain a first solution, and then the first solution and liquid B were mixed at a volume ratio of 1:3 to obtain an antibacterial hemostatic hydrogel loaded with composite nanoparticles (DXMS@mPDA@Gel).

[0068] Example 2

[0069] The preparation method of liquid B in step (2) is: adding 8 mg of hemostatic polypeptide to 5 mL of 5 wt% oxidized dextran solution at 25° C. and reacting for 2 hours; the nucleotide sequence of the hemostatic polypeptide is arginine (R)-alanine (A)-aspartic acid (D)-alanine (A)-arginine (R)-glycine (G)-aspartic acid (D)-lysine (K).

[0070] (2) Synthesis of blank hydrogel: 2 wt% of liquid A and 5 wt% of liquid B (using distilled water as solvent) were mixed in a volume ratio of 1:2 to obtain a blank hydrogel.

[0071] The rest is the same as in Example 1.

[0072] Example 3

[0073] The preparation method of the solution A is as follows: first synthesize the antibacterial agent, then mix 10 mg of the antibacterial agent with 5 mL of 3% carboxymethyl chitosan solution (CMC) for 4 hours, and then dialyze with a 1000 KDa dialysis bag for 24 hours to obtain the solution.

[0074] The antibacterial agent (EPDMDAC) is synthesized as follows: 0.01 mmol of dimethyldodecyl tertiary amine and 0.04 mmol of epichlorohydrin are reacted at 80°C for 1 hour. When the mixed reactant solution turns from transparent to dark yellow, the reaction product is precipitated with diethyl ether and centrifuged to obtain crude EPDMDAC. The crude EPDMDAC is then ultrasonically washed with diethyl ether three times and dried in a vacuum to obtain the antibacterial agent (EPDMDAC).

[0075] The raw materials for preparing liquid B in step (2) include a cross-linking agent and a hemostatic polypeptide.

[0076] The cross-linking agent is oxidized dextran (OD), and the preparation method of the oxidized dextran is as follows: dissolving 5 g of dextran in 250 mL of distilled water to obtain a dextran solution, then dissolving sodium periodate in 5 mL of distilled water to obtain a sodium periodate solution, adding the sodium periodate solution dropwise to the dextran solution, and then stirring at room temperature in the dark for 3.5 hours to obtain a mixture, finally, adding 3 mL of ethylene glycol to the mixture to react unreacted sodium periodate, and finally stirring for another 1 hour, dialyzing the resulting product against distilled water (MWCO 1400Da) for 3 days and freeze-drying to obtain the oxidized dextran.

[0077] The preparation method of liquid B in step (2) is as follows: 10 mg of hemostatic polypeptide is added to 5 ml of 5 wt% oxidized dextran solution at 25° C. and reacted for 2 hours; the nucleotide sequence of the hemostatic polypeptide is arginine (R)-alanine (A)-aspartic acid (D)-alanine (A)-arginine (R)-glycine (G)-aspartic acid (D)-lysine (K).

[0078] (2) Synthesis of blank hydrogel: 2 wt% of liquid A and 5 wt% of liquid B (using distilled water as solvent) were mixed in a volume ratio of 1:4 to obtain a blank hydrogel.

[0079] The rest is the same as in Example 1.

[0080] Comparative Example 1

[0081] The preparation method of the solution A is as follows: first synthesize the antibacterial agent, then mix 25 mg of the antibacterial agent with 5 mL of 3% carboxymethyl chitosan solution (CMC) for reaction for 3 hours, and then dialyze with a 1000 KDa dialysis bag for 24 hours to obtain the solution.

[0082] The rest is the same as in Example 1.

[0083] Comparative Example 2

[0084] The preparation method of liquid B in step (2) is: adding 20 mg of hemostatic polypeptide to 5 ml of 5wt% oxidized dextran solution at 25°C and reacting for 1.5 hours; the nucleotide sequence of the hemostatic polypeptide is arginine (R)-alanine (A)-aspartic acid (D)-alanine (A)-arginine (R)-glycine (G)-aspartic acid (D)-lysine (K).

[0085] The rest is the same as in Example 1.

[0086] Comparative Example 3

[0087] (2) Synthesis of blank hydrogel: 2 wt% of liquid A and 5 wt% of liquid B (using distilled water as solvent) were mixed in a volume ratio of 1:5 to obtain a blank hydrogel.

[0088] The rest is the same as in Example 1.

[0089] Comparative Example 4

[0090] A method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles comprises the following steps: (1) synthesizing composite nanoparticles; the composite nanoparticles are formed by loading a hydrophobic drug onto mesoporous polydopamine nanospheres; (2) synthesizing a blank hydrogel; the blank hydrogel is formed by mixing liquid A and liquid B; and (3) synthesizing a drug-loaded hydrogel; the drug-loaded hydrogel is formed by mixing the blank hydrogel and the composite nanoparticles.

[0091] The hydrophobic drug is dexamethasone (DXMS).

[0092] The synthesis method of the composite nanoparticles in step (1) is as follows:

[0093] First, 1.0 g of nonionic surfactant poloxamer and 0.5 g of dopamine were dissolved in 100 mL of 50% ethanol solution, covered with plastic wrap, and holes were evenly pierced on the plastic wrap with a 200 uL pipette tip. The mixture was stirred at room temperature on a stirring table until dissolved to obtain a clear and transparent solution. Then, 2 mL of 3,3',5,5'-tetramethylbenzidine (TMB) was added dropwise at a speed of 500 rpm / min, and stirred for 30 min to obtain a white milky solution. At the same speed, the temperature was adjusted to 25 ° C, 5 mL of ammonia water was added dropwise, and a black solution was obtained after stirring for 2 h. The reaction was continued for 4 h to obtain a reaction solution. 2 mL of the reaction solution was aspirated into a 2 mL centrifuge tube (24 2 mL centrifuge tubes were prepared in advance), and the mixture was centrifuged in a refrigerated centrifuge (the centrifugal speed was 13500 rpm / min and the time was 15 min). The supernatant was discarded and 2 mL Wash with 50% ethanol and shake well, continue centrifugation, repeat the above operation twice, and finally add 500 μL pure water to dissolve the precipitate after centrifugation, and resuspend by ultrasonication to obtain mesoporous polydopamine nanosphere solution (mPDA);

[0094] A 1 mL, 1 mg / mL dexamethasone (DXMS) solution was added to a 1 mL, 1 mg / mL mesoporous polydopamine nanosphere solution. After stirring at 400 rpm / min for 24 h, the mixture was centrifuged and washed to obtain a composite nanomaterial (mPDA@DXMS).

[0095] The raw material for preparing liquid A in step (2) is a natural polymer, and the natural polymer is carboxymethyl chitosan. Carboxymethyl chitosan is dissolved in water to prepare liquid A with a mass percentage of 2wt%.

[0096] The raw material for preparing liquid B in step (2) is a cross-linking agent.

[0097] The cross-linking agent is oxidized dextran (OD), and the preparation method of the oxidized dextran is as follows: dissolving 5 g of dextran in 250 mL of distilled water to obtain a dextran solution, then dissolving 5 g of sodium periodate in 5 mL of distilled water to obtain a sodium periodate solution, adding the sodium periodate solution dropwise to the dextran solution, and then stirring at room temperature in the dark for 3.5 hours to obtain a mixture, finally, adding 3 mL of ethylene glycol to the mixture to react unreacted sodium periodate, and finally stirring for another 1 hour, dialyzing the resulting product against distilled water (MWCO 3500Da) for 3 days and freeze-drying to obtain the oxidized dextran.

[0098] Oxidized dextran was dissolved in water to prepare a solution B with a mass percentage of 5 wt%.

[0099] (2) Synthesis of blank hydrogel: 2 wt% of liquid A and 5 wt% of liquid B (using distilled water as solvent) were mixed in a volume ratio of 1:3 to obtain a blank hydrogel.

[0100] (3) Synthesis of drug-loaded hydrogel: The composite nanoparticle solution was dispersed in liquid A at a volume ratio of 1:1 to obtain a first solution, and then the first solution and liquid B were mixed at a volume ratio of 1:3 to obtain an antibacterial hemostatic hydrogel loaded with composite nanoparticles (DXMS@mPDA@Gel).

[0101] Performance evaluation

[0102] (1) Determination of encapsulation efficiency and loading rate of composite nanoparticles (DXMS@mPDA):

[0103] 1. Preparation of a standard curve: Weigh 5 mg of dexamethasone standard substance into a beaker, add an appropriate amount of ultrapure water to dissolve, then transfer to a 5 mL volumetric flask and dilute to volume to prepare a 1 mg / mL dexamethasone solution. Dilute to 25, 12.5, 6.25, 3.125, and 1.5625 μg / mL standard solutions. Measure the absorbance at 242 nm using a UV-2600i spectrophotometer. Plot a standard curve with the dexamethasone concentration as the abscissa and the absorbance as the ordinate.

[0104] 2. The DXMS@mPDA synthesized in the examples and comparative examples was ultrafiltered through a 100 kd ultrafiltration tube. The filtrates below and above the ultrafiltration tube were collected and the volume difference between the two was calculated. The following solution was then appropriately diluted and the absorbance of the solution was measured using a UV-2600i. The absorbance was substituted into the standard curve to calculate the drug mass in the following solution. The drug mass in the solution was subtracted from the total added mass to obtain the loaded drug mass. The encapsulation efficiency and loading rate were calculated according to the following formula:

[0105] Encapsulation efficiency = loaded cedimetasone mass / theoretical total added mass of cedimetasone Loading rate = loaded cedimetasone mass / sum of the mass of mesoporous polydopamine nanospheres and loaded cedimetasone

[0106] The test results are shown in Table 1.

[0107] (2) Material characterization.

[0108] 1. Particle size and potential test

[0109] The nanoparticles were appropriately diluted with ultrapure water (10 times), and then the particle size and potential of the samples were tested using the particle size and potential mode of the Zetasizer Nano ZS90 particle size analyzer. As shown in the figure, the average particle size of mPDA is 85 nm and the potential is -38.3 mV, and the average particle size of mPDA@DXMS is 80 nm and the potential is -41.5 mV.

[0110] 2. Transmission electron microscopy (TEM) test:

[0111] After diluting the sample 10 times with ultrapure water, take 70uL and drop it on a special copper grid. After 3 minutes, remove the excess liquid with filter paper, then add 70uL of 2% uranyl acetate for negative staining. After 3 minutes, remove the excess liquid with filter paper, dry it naturally, and observe the morphology of the synthesized nanoparticles with a TEM electron microscope, as shown in the figure.

[0112] 3. Sample stability test

[0113] In order to evaluate the stability of the composite nanoparticles, the composite nanoparticles and PBS solution were mixed in a ratio of 1:1, and then allowed to stand at room temperature. The particle size was tested at 2, 4, 6, 8, 10, 12, and 24 hours to evaluate the particle size stability of the samples. As the standing time increased, the average particle size of the composite nanoparticles changed less, proving that mPDA@DXMS has good stability.

[0114] 4. Sample Release Analysis

[0115] In order to evaluate the drug release behavior of the composite nanoparticle system, an in vitro drug release experiment was performed. Specifically, 2 mL of composite nanoparticles were sealed in a dialysis bag and placed in a sample bottle containing 10 mL of pH 7.4 buffer, respectively. The mixture was shaken continuously at 37 ° C and 150 r / min. Every 2 hours (when the time exceeds 10 hours, the time point becomes every 5 hours), 2 mL of the solution was centrifuged, and then 2 mL of the corresponding PBS was added to the centrifugal product. The absorbance at 250 nm in the supernatant was measured by ultraviolet spectroscopy. The release amount at different times was calculated based on the standard curve. As shown in the figure, within the time range of 2-24 hours, the drug release rate of the composite nanoparticles increased from 15.13% to 72.95%.

[0116] 5. UV-visible absorption spectrum test: The UV-visible absorption spectra of DXMS solution, mPDA, and mPDA@DXMS were measured using a UV-2600i spectrophotometer.

[0117] (2) Related tests and results of hydrogel materials.

[0118] 1. Scanning Electron Microscopy (SEM):

[0119] 1.1 Sample preparation: Stick the conductive glue on the sample table, then stick a clean thin copper sheet on the conductive glue, drop the sample on the copper sheet in small amounts and multiple times, and wait for the solvent to evaporate and dry completely.

[0120] Preparation of hydrogel samples: Cut freshly prepared hydrogel samples into 1*1*1cm 3The square gel blocks were added with distilled water and placed in a 4°C refrigerator for 24 h. They were then quickly frozen in liquid nitrogen for 30 min and immediately placed in a freeze dryer for 24 h. The block gel samples were directly glued to the conductive adhesive.

[0121] 1.2 Gold spraying test:

[0122] Gold was sputtered for 45 seconds using an Oxford Quorum SC7620 sputter coater at 10 mA. Sample morphology was then captured using a TESCAN MIRA LMS scanning electron microscope at an accelerating voltage of 3 kV. The morphologies of the blank hydrogel (Gel) and the drug-loaded hydrogel (DXMS@mPDA@Gel) were observed. As shown in the figure, both the Gel and the DXMS@mPDA@Gel composite hydrogel exhibited the typical three-dimensional network structure of a gel. Furthermore, compared to the blank gel, uniformly dispersed composite nanoparticles with a particle size of approximately 120 nm were observed within the pores of the DXMS@mPDA@Gel composite hydrogel. This is consistent with the particle size of the DXMS@mPDA composite nanoparticles, indicating that the DXMS@mPDA@Gel composite hydrogel was successfully synthesized.

[0123] 2. Fourier transform infrared spectroscopy

[0124] Take 20mg of dry gel sample and place it between two glass slides to form a sheet. In a dry environment, place the ATR accessory in the optical path of the spectrometer, scan the air background, and then place the block / film sample surface close to the crystal surface of the ATR accessory. Then collect the infrared spectrum of the sample with a resolution of 4cm. -1 , the number of scans was 32, and the test wave number range was 500-4000cm -1 , as shown in the figure, at 1471cm -1 The characteristic peak of the antibacterial agent appears at 3300 cm, indicating that dimethyl dodecyl tertiary amine is successfully grafted onto carboxymethyl chitosan, as shown in the figure. -1 The obvious change of the peak at 47° may be caused by the grafting of the hemostatic peptide RADARGDK onto the oxidized dextran.

[0125] 3. Rheological properties and self-healing performance tests.

[0126] Hydrogel samples with a diameter of 20 mm and a height of 2 mm were prepared. The rheological properties of the hydrogels were characterized using a Mars 60 rheometer. An oscillation rate sweep test was performed at 25 ± 0.2°C with γ = 0.1-1000% and f = 1 Hz. The shear rate-viscosity curve was obtained by varying only the frequency (0.1-100 Hz) while keeping the temperature and strain (γ = 1%) fixed. The rheological properties of the hydrogels were measured using the rheometer.

[0127] Meanwhile, gels were labeled with FITC (yellow-green fluorescein) and rhodamine B (red fluorescein) respectively. After the gels were formed, they were cut with a scalpel. Two gel blocks of different colors were spliced together. After being placed for a period of time, the changes in the hydrogel were observed.

[0128] The results are shown in the figure. (1) When the strain range is 0.1 - 100%, the G’ of the gel is distributed between 30 - 40 Pa. The material mainly undergoes elastic deformation and the gel structure is well maintained. The G” is distributed between 0 - 10 Pa, and G’ is greater than G”. When the strain range is greater than 100%, G’ and G” intersect. At this time, the sample is at the gel-sol transition point, that is, the state of the sample begins to change. When G’ < G”, the material mainly undergoes viscous deformation, indicating that the sample mainly exhibits liquid characteristics, indicating that the gel structure collapses at this time. (2) The viscosity of the prepared hydrogel decreases with the increase of stress, that is, the shear thinning effect appears. All the above results indicate that the hydrogel has injectability. Its visualization results are shown in the inset. The gel labeled with FITC fluorescence can be injected into a uniform strip by a syringe, thus meeting the treatment of wounds with different shapes. Gel self-healing refers to the ability of the material to approach or reach the state before damage in terms of morphology, performance, etc. after being damaged externally and self-repaired. As shown in Figure (4), gels were labeled with FITC (yellow-green fluorescein) and rhodamine B (red fluorescein) respectively. After the gels were formed, they were cut with a scalpel. Two gel blocks of different colors were spliced together. After being placed for 5 min, the colors at the interface were significantly fused, indicating that molecules moved at the interface at this time, and the spliced gap was significantly healed. The above shows that the gel has good self-healing performance. This feature is beneficial for the gel to self-bond after injection, maintain a good extended state of coverage, and maintain the contact surface at the lesion site.

[0129] 4. Gel degradation analysis

[0130] 4.1 Enzymatic hydrolysis

[0131] Take a certain mass (W0) of the hydrogel and put it into PBS solution. Add the corresponding degradation enzyme. Regularly take out the hydrogel. After taking it out, rinse it with deionized water, freeze-dry it, and measure the mass (W t ). Calculate the degradation rate of the hydrogel.

[0132] Degradation rate (%) = (W0 - W t ) / W0 × 100%

[0133] The specific operation is as follows: add 2.5g trypsin and 25mg lysozyme solid to 50mL PBS solution with pH=7.4, wait for the solid to dissolve and form a uniform solution. Weigh 50mg (W0) of freeze-dried hydrogel and place it in a 10mL sample bottle. Take 5mL of the complex enzyme solution and add it to the sample bottle, then place it in an oscillating incubator (37℃, 70rpm).

[0134] Samples were taken out regularly (1, 3, 5, 7, 14, 21 days), rinsed with deionized water and placed in a -20 °C refrigerator overnight. The next day, samples were taken out and freeze-dried for 12 hours. The mass of the freeze-dried hydrogel (W t ), and the degradation rate of the hydrogel was calculated according to the formula.

[0135] As shown in the figure, hydrogel materials have excellent biocompatibility and biodegradability. Under the physiological environment of the body, they can be degraded from high-molecular-weight and macromolecular substances into harmless small molecules through hydrolysis and enzymatic hydrolysis. These small-molecule degradation products are usually already present in the body and are completely absorbed and excreted through the body's metabolism, with no toxic side effects. The degradation performance of the hydrogel was verified using an enzymatic hydrolysis experiment.

[0136] The mass loss curves of Gel and DXMS@mPDA@Gel hydrogels after degradation in a complex enzyme solution at pH 7.4 are shown in the figure. The mass loss of the Gel and DXMS@mPDA@Gel hydrogels gradually increased over time, with degradation rates of 75% and 70% for Gel and DXMS@mPDA@Gel hydrogels, respectively, at 7 days. This trend slowed after 7 days. This is attributed to the cleavage of Schiff base bonds, cation-π bonds, and electrostatic interactions in the complex enzyme solution. Furthermore, the addition of DXMS@mPDA nanoparticles significantly reduced the mass loss of the gel under the same conditions. This may be due to the introduction of mPDA promoting additional crosslinking points within the hydrogel matrix, resulting in a more stable internal structure of the hydrogel and, consequently, a reduction in gel loss.

[0137] 5. Adhesion properties of gel

[0138] First, 10 mL of antibacterial and hemostatic hydrogel loaded with composite nanoparticles was added to a circular culture dish with a diameter of 35 mm. Then, fresh mouse spleen, kidney, heart, lung, and liver were placed in the circular container for culture. After 3 minutes, the culture dish was inverted.

[0139] As shown in the figure, the hydrogel is transparent and colloid-like. When the culture dish with fresh organs adhered to it is inverted, the tissues are firmly adhered to the gel. Moreover, the organs do not fall off when inverted, indicating that the gel can adhere to various fresh organs. From the above results, it can be seen that the gel prepared by the present invention has good adhesion properties to mouse heart, liver, spleen, lung, and kidney tissues.

[0140] 6. Antibacterial properties of gel

[0141] The antibacterial activity of the hydrogel can also be tested through a plate diffusion test. All hydrogels with a diameter of d = 10 mm were sterilized under ultraviolet light for 0.5 h. Then, different samples were placed on agar plates coated with a quantitative bacterial solution and incubated in a 37°C incubator for 24 h. The antibacterial properties of the hydrogels were evaluated based on the diameter of the inhibition zone. The results are shown in Figure 14. (a) is a control experiment without the addition of a blank hydrogel, (b) is the blank hydrogel in Comparative Example 4, which was not grafted with an antibacterial agent and had a smaller inhibition zone, and (c) is the blank hydrogel grafted with an antibacterial agent in Example 1, which had a significantly larger inhibition zone.

[0142] 7. Gel hemostatic properties

[0143] Liver injury hemostasis experiment: First, the experimental animals were fasted for 24 hours. The next day, they were weighed and anesthetized intramuscularly according to the corresponding dose. The limbs and head were then fixed to the operating table, the trachea was intubated and connected to the respiratory anesthesia machine. The abdominal skin was then prepared and disinfected, and the liver was exposed under sterile conditions. After being freed, a wound about 0.5 cm long and 0.05 cm deep was made on the surface of the liver with a scalpel. After observing the blood flow, an area of ​​5*5 cm was cut. 2 A gauze pad was placed on the liver, and the hydrogel dressing was attached to the wound surface. After slight pressure was applied, the wound was observed to see if bleeding had stopped after the same period of time. The results are shown in FIG15 . FIG15 (a) shows a control experiment in which no hydrogel was added. FIG15 (b) shows a blank hydrogel in Comparative Example 4 in which no hemostatic polypeptide was grafted. It was clearly found that the wound had not stopped bleeding. FIG15 (c) shows a blank hydrogel grafted with a hemostatic polypeptide in Example 1. It was clearly found that the wound had stopped bleeding.

[0144] The above-mentioned self-healing and adhesion performance tests were performed on the nanoparticle-loaded antibacterial hemostatic hydrogels prepared in Example and Comparative Examples 1-3. The test results are shown in Table 1.

[0145] The evaluation of the healing performance test is the placement time. The longer the placement time, the worse the self-healing performance.

[0146] Table 1

[0147] Compared with Example 1, the excessive amount of antibacterial agent in Comparative Example 1 will lead to an excessively high grafting rate, resulting in the occupation of the connectable active sites in the composite nanoparticles, which will reduce the self-healing performance of the hydrogel. The excessive amount of hemostatic polypeptide in Comparative Example 2 is similar to the principle of Comparative Example 1, which will also reduce the self-healing performance of the hydrogel. The ratio of liquid A and liquid B in Comparative Example 3 is reduced, which will lead to a decrease in the cross-linking density of the blank hydrogel and a decrease in the self-healing performance.

Claims

1. A method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles, characterized in that: The method comprises the following steps: (1) synthesizing composite nanoparticles; the composite nanoparticles are formed by loading hydrophobic drugs on mesoporous polydopamine nanospheres; (2) synthesizing blank hydrogels; the blank hydrogels are formed by mixing liquid A and liquid B; and (3) synthesizing drug-loaded hydrogels; the drug-loaded hydrogels are formed by mixing blank hydrogels and composite nanoparticles.

2. The method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles according to claim 1, characterized in that: The raw materials for preparing liquid A in step (2) include tertiary amine compounds, natural polymers and epihalohydrin.

3. The method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles according to claim 2, characterized in that: The preparation method of the liquid A is as follows: firstly synthesize the antibacterial agent, and then mix the antibacterial agent with the natural polymer solution for reaction for 3-6 hours to obtain the liquid A.

4. The method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles according to claim 3, characterized in that: In the preparation method of liquid A, the usage amount of the antibacterial agent is 10-20 mg.

5. The method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles according to claim 1, characterized in that: The raw materials for preparing liquid B in step (2) include a cross-linking agent and a hemostatic polypeptide.

6. The method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles according to claim 5, characterized in that: The preparation method of liquid B in step (2) is: mixing the cross-linking agent and the hemostatic polypeptide at 20-30° C. and reacting for 1-4 hours to obtain the liquid B.

7. The method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles according to claim 6, characterized in that: The usage amount of the hemostatic polypeptide is 5-15 mg.

8. The method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles according to claim 1, characterized in that: In the step (2), the volume ratio of liquid A to liquid B is 1:(2-4).

9. The method for preparing an antibacterial hemostatic hydrogel loaded with composite nanoparticles according to claim 1, characterized in that: The mass percentage of the A liquid is 1-3wt%, and the mass percentage of the B liquid is 3-6wt%.

10. Use of the antibacterial hemostatic hydrogel loaded with composite nanoparticles according to any one of claims 1 to 9 in preparing wound repair materials.

Citation Information

Patent Citations

  • Antibacterial adhesion injectable hydrogel dressing, preparation method and applications thereof

    CN108912352A

  • Double-drug-loading polysaccharide-based self-healing hydrogel and preparation method thereof

    CN113577376A

  • Preparation method of injectable in-situ cross-linked hydrophobic drug sustained-release hydrogel

    CN114557957A

  • Antibacterial antifouling cellulose acetate membrane and preparation method thereof

    CN114989476A

  • Soluble microneedle for mediating glucocorticoid-loaded mesoporous polydopamine nanoparticles and preparation method of soluble microneedle

    CN115969770A